Thermoluminescent dosimetry of the selectseed 125I interstitial brachytherapy seed

Radiation Safety Assessment in Prostate Cancer Treatment: A Predictive Approach for I-125 Brachytherapy

This study uses Monte Carlo simulation and experimental measurements to develop a predictive model for estimating the external dose rate associated with permanent radioactive source implantation in prostate cancer patients. The objective is to estimate the accuracy of the patient's external dose rate measurement. First, I-125 radioactive sources were implanted into Mylar window water phantoms to simulate the permanent implantation of these sources in patients. Water phantom experimental measurement was combined with Monte Carlo simulation to develop predictive equations, whose performance was verified against external clinical data. The model's accuracy in predicting the external dose rate in patients with permanently implanted I-125 radioactive sources was high (R2 = 0.999). A comparative analysis of the experimental measurements and the Monte Carlo simulations revealed that the maximum discrepancy between the measured and calculated values for the water phantom was less than 5.00%. The model is practical for radiation safety assessments, enabling the evaluation of radiation exposure risks to individuals around patients with permanently implanted I-125 radioactive sources.

Validation of the TOPAS Monte Carlo toolkit for LDR brachytherapy simulations

PURPOSE

This work has the purpose of validating the Monte Carlo toolkit TOol for PArticle Simulation (TOPAS) for low-dose-rate (LDR) brachytherapy uses.

METHODS AND MATERIALS

Simulations of 12 LDR sources and 2 COMS eye plaques (10 mm and 20 mm in diameter) and comparisons with published reference data from the Carleton Laboratory for Radiotherapy Physics (CLRP), the TG-43 consensus data and the TG-129 consensus data were performed. Sources from the IROC Houston Source Registry were modeled. The OncoSeed 6711 and the SelectSeed 130.002 were also modeled for historical reasons. For each source, the dose rate constant, the radial dose function and the anisotropy functions at 0.5, 1 and 5 cm were extracted. For the eye plaques (loaded with ¹²⁵I sources), dose distribution maps, dose profiles along the central axis and transverse axis were calculated.

RESULTS

Dose rate constants for 11 of the 12 sources are within 4% of the consensus data and within 2% of the CLRP data. The radial dose functions and anisotropy functions are mostly within 2% of the CLRP data. In average, 92% of all voxels are within 1% of the CLRP data for the eye plaques dose distributions. The dose profiles are within 0.5% (central axis) and 1% (transverse axis) of the reference data.

CONCLUSION

The TOPAS MC toolkit was validated for LDR brachytherapy applications. Single-seed and multi-seed results agree with the published reference data. TOPAS has several benefits such as a simplified approach to MC simulations and an accessible brachytherapy package including comprehensive learning resources.

Effect of improved TLD dosimetry on the determination of dose rate constants for (125)I and (103)Pd brachytherapy seeds

PURPOSE

To more accurately account for the relative intrinsic energy dependence and relative absorbed-dose energy dependence of TLDs when used to measure dose rate constants (DRCs) for (125)I and (103)Pd brachytherapy seeds, to thereby establish revised "measured values" for all seeds and compare the revised values with Monte Carlo and consensus values.

METHODS

The relative absorbed-dose energy dependence, f(rel), for TLDs and the phantom correction, Pphant, are calculated for (125)I and (103)Pd seeds using the EGSnrc BrachyDose and DOSXYZnrc codes. The original energy dependence and phantom corrections applied to DRC measurements are replaced by calculated (f(rel))(-1) and Pphant values for 24 different seed models. By comparing the modified measured DRCs to the MC values, an appropriate relative intrinsic energy dependence, kbq (rel), is determined. The new Pphant values and relative absorbed-dose sensitivities, SAD (rel), calculated as the product of (f(rel))(-1) and (kbq (rel))(-1), are used to individually revise the measured DRCs for comparison with Monte Carlo calculated values and TG-43U1 or TG-43U1S1 consensus values.

RESULTS

In general, f(rel) is sensitive to the energy spectra and models of the brachytherapy seeds. Values may vary up to 8.4% among (125)I and (103)Pd seed models and common TLD shapes. Pphant values depend primarily on the isotope used. Deduced (kbq (rel))(-1) values are 1.074 ± 0.015 and 1.084 ± 0.026 for (125)I and (103)Pd seeds, respectively. For (1 mm)(3) chips, this implies an overall absorbed-dose sensitivity relative to (60)Co or 6 MV calibrations of 1.51 ± 1% and 1.47 ± 2% for (125)I and (103)Pd seeds, respectively, as opposed to the widely used value of 1.41. Values of Pphant calculated here have much lower statistical uncertainties than literature values, but systematic uncertainties from density and composition uncertainties are significant. Using these revised values with the literature's DRC measurements, the average discrepancies between revised measured values and Monte Carlo values are 1.2% and 0.2% for (125)I and (103)Pd seeds, respectively, compared to average discrepancies for the original measured values of 4.8%. On average, the revised measured values are 4.3% and 5.9% lower than the original measured values for (103)Pd and (125)I seeds, respectively. The average of revised DRCs and Monte Carlo values is 3.8% and 2.8% lower for (125)I and (103)Pd seeds, respectively, than the consensus values in TG-43U1 or TG-43U1S1.

CONCLUSIONS

This work shows that f(rel) is TLD shape and seed model dependent suggesting a need to update the generalized energy response dependence, i.e., relative absorbed-dose sensitivity, measured 25 years ago and applied often to DRC measurements of (125)I and (103)Pd brachytherapy seeds. The intrinsic energy dependence for LiF TLDs deduced here is consistent with previous dosimetry studies and emphasizes the need to revise the DRC consensus values reported by TG-43U1 or TG-43U1S1.

Dosimetric characterization and output verification for conical brachytherapy surface applicators. Part I. Electronic brachytherapy source

PURPOSE

Historically, treatment of malignant surface lesions has been achieved with linear accelerator based electron beams or superficial x-ray beams. Recent developments in the field of brachytherapy now allow for the treatment of surface lesions with specialized conical applicators placed directly on the lesion. Applicators are available for use with high dose rate (HDR)(192)Ir sources, as well as electronic brachytherapy sources. Part I of this paper will discuss the applicators used with electronic brachytherapy sources; Part II will discuss those used with HDR (192)Ir sources. Although the use of these applicators has gained in popularity, the dosimetric characteristics including depth dose and surface dose distributions have not been independently verified. Additionally, there is no recognized method of output verification for quality assurance procedures with applicators like these. Existing dosimetry protocols available from the AAPM bookend the cross-over characteristics of a traditional brachytherapy source (as described by Task Group 43) being implemented as a low-energy superficial x-ray beam (as described by Task Group 61) as observed with the surface applicators of interest.

METHODS

This work aims to create a cohesive method of output verification that can be used to determine the dose at the treatment surface as part of a quality assurance/commissioning process for surface applicators used with HDR electronic brachytherapy sources (Part I) and(192)Ir sources (Part II). Air-kerma rate measurements for the electronic brachytherapy sources were completed with an Attix Free-Air Chamber, as well as several models of small-volume ionization chambers to obtain an air-kerma rate at the treatment surface for each applicator. Correction factors were calculated using MCNP5 and EGSnrc Monte Carlo codes in order to determine an applicator-specific absorbed dose to water at the treatment surface from the measured air-kerma rate. Additionally, relative dose measurements of the surface dose distributions and characteristic depth dose curves were completed in-phantom.

RESULTS

Theoretical dose distributions and depth dose curves were generated for each applicator and agreed well with the measured values. A method of output verification was created that allows users to determine the applicator-specific dose to water at the treatment surface based on a measured air-kerma rate.

CONCLUSIONS

The novel output verification methods described in this work will reduce uncertainties in dose delivery for treatments with these kinds of surface applicators, ultimately improving patient care.

Experimental determination of dosimetry parameters for Sinko (125)I seed source using a modified polystyrene phantom

Successful treatment for permanent implant brachytherapy is based on accurate measurement of dosimetry parameters for the seed sources. Literature describes the application of various types of phantom to determine the AAPM TG-43 dosimetry parameters for permanent implant seeds. Previously we created a new type of phantom used to measure the dosimetry parameters of a high dose-rate (192)Ir source. In this study, we modified the phantom to suit to a common type of (125)I seed source (Sinko BT-125-1). The dose-rate constant, radial dose function and anisotropy function of this source were measured in detail and compared with the published values of other similar in-design (125)I seed sources. The experimental results exhibit fairly small measurement uncertainties and good self-consistency. The modified phantom is demonstrated on the measurement of dosimetry parameters for the Sinko BT-125-1 (125)I seed, however, it could easily be used for similar measurements of other permanent implantation seed sources.

Thermoluminescent and Monte Carlo dosimetry of IR06-103Pd brachytherapy source

This work presents experimental dosimetry results for a new P103d brachytherapy seed, in accordance with the AAPM TG‐43U1 recommendation that all new low‐energy interstitial brachytherapy seeds should undergo one Monte Carlo (MC) and at least one experimental dosimetry characterization. Measurements were performed using TLD‐GR200A circular chip dosimeters using standard methods employing thermoluminescent dosimeters in a Perspex phantom. The Monte Carlo N‐particle (MCNP) code, version 5 was used to evaluate the dose‐rate distributions around this model P103d source in water and Perspex phantoms. The consensus value for dose‐rate constant of the IR06‐P103d source was found equal to 0.690 cG⋅h−1⋅U−1. The anisotropy function, F(r, θ), and the radial dose function, gL(r), of the seed were measured in Perspex phantom and calculated in both Perspex and liquid water phantom. The measured values were also found in good agreement with corresponding MC calculations.

PACS number: 87.53.Jw

Development of a spherical (125)i-brachytherapy seed for its application in the treatment of eye and prostate cancer

Palladium-coated silver beads of 0.5 mm (phi) were used to adsorb (125)I, encapsulated inside a titanium capsule by an Nd:YAG laser, for use as a brachytherapy source. Experimental conditions, such as feed activity, carrier concentration, and reaction time, were optimized for the maximum adsorption of (125)I. Uniform distribution of radioactivity on the source core was ascertained by the autoradiography technique. Leachability of (125)I was found to be <0.01%. The dose-rate constant of the new source was estimated to be 1.045 cGyh(-1)U(-1). This newly developed source could be an alternative to other (125)I sources.

Postimplant Dosimetry Using a Monte Carlo Dose Calculation Engine: A New Clinical Standard

PURPOSE

To use the Monte Carlo (MC) method as a dose calculation engine for postimplant dosimetry. To compare the results with clinically approved data for a sample of 28 patients. Two effects not taken into account by the clinical calculation, interseed attenuation and tissue composition, are being specifically investigated.

METHODS AND MATERIALS

An automated MC program was developed. The dose distributions were calculated for the target volume and organs at risk (OAR) for 28 patients. Additional MC techniques were developed to focus specifically on the interseed attenuation and tissue effects.

RESULTS

For the clinical target volume (CTV) D(90) parameter, the mean difference between the clinical technique and the complete MC method is 10.7 Gy, with cases reaching up to 17 Gy. For all cases, the clinical technique overestimates the deposited dose in the CTV. This overestimation is mainly from a combination of two effects: the interseed attenuation (average, 6.8 Gy) and tissue composition (average, 4.1 Gy). The deposited dose in the OARs is also overestimated in the clinical calculation.

CONCLUSIONS

The clinical technique systematically overestimates the deposited dose in the prostate and in the OARs. To reduce this systematic inaccuracy, the MC method should be considered in establishing a new standard for clinical postimplant dosimetry and dose-outcome studies in a near future.

Monte Carlo and experimental dosimetry of an I125 brachytherapy seed

We have performed a comprehensive dosimetric characterization of the Oncura model 6711 125I seed using both experimental [LiF thermoluminscent dosimetry (TLD)] and theoretical (Monte Carlo photon transport) methods. In addition to determining the dosimetric parameters of the 6711, this report quantified: (1) the angular dependence of LiF TLD energy response functions for both point and volume detectors in water, poly(methylmethacrylate), and solid water media; and (2) the contribution of underlying geometric uncertainties to the overall uncertainty of Monte Carlo derived dosimetric parameters according to the National Institute of Standards and Technology Report 1297 methodology. The theoretical value for the dose rate constant in water was 0.942 cGy U(-1) h(-1)+/-1.76% [combined standard uncertainty (CSU) with coverage factor k=1] and the experimental value was 0.971 cGy U(-1) h(-1)+/-6.1%. Agreement between experimental and theoretical radial dose function values was well within the k= 1 CSU, while agreement between experimental and theoretical anisotropy function values was within the k= 1 CSU only after incorporating the use of polar angle-dependent energy response functions. The angular dependence of the relative energy response was found to have a complex and significant dependence on measurement medium and internal geometry of the source.

Studies on the production and quality assurance of miniature 125I radioactive sources suitable for treatment of ocular and prostate cancers

(125)I sources were prepared by adsorption of (125)I on palladium-coated silver wires. The effect of reducing agent on percentage adsorption of (125)I was studied and the amount of adsorbed activity on source core was studied by repeated adsorption cycles. The activity per source in the sources produced from the same batch varied with coefficient of variation (i.e. the ratio of standard deviation to mean multiplied by 100) less than 10%. The unencapsulated source exhibited low leachability (< 0.01%). The laser parameters were optimized to obtain quality welds with negligible leak rate. The sources were laser-encapsulated in titanium capsules of 0.8 mm (OD) x 4.5mm (l). The release of radioactivity from encapsulated sources in an immersion test at 50 degrees C for 5 h was <5 nCi (185 Bq). The surface contamination on the sealed capsules was found to be<0.05 nCi or 1.85 Bq per source. The sources were used in the treatment of a child having retinoblastoma.

Monte Carlo and thermoluminescence dosimetry of the new IsoSeed® model I25.S17 I125 interstitial brachytherapy seed

Monte Carlo simulation and experimental thermoluminescence dosimetry were utilized for the dosimetric characterization of the new IsoSeed model I25.S17 125I interstitial brachytherapy seed. The new seed design is similar to that of the selectSeed and 6711 seeds, with the exception of its molybdenum marker. Full dosimetric data are presented following the recommendations in the Update of the AAPM Task Group 43 report (TG-43U1). A difference of 3.3% was found between Monte Carlo dose rate constant results calculated by air kerma strengths from simulations using a point detector and a detector resembling the solid angle subtended to the seed by the Wide Angle Free Air Chamber (WAFAC) in the primary standard calibration geometry. Following the TG-43U1 recommendations, an average value of lambdaMC = (0.929 +/- 0.014) cGy h(-1) U(-1) was adopted for the new seed. This value was then averaged with the measured value of lambdaEXP = (0.951 +/- 0.044) cGy h(-1) U(-1) to yield the proposed dose rate constant for the new seed that is equal to lambda = (0.940 +/- 0.051) cGy h(-1) U(-1). The Monte Carlo calculated radial dose function and two-dimensional (2-D) anisotropy function results for the new seed were found in agreement with experimental results to within statistical uncertainty of repeated measurements. Monte Carlo simulations were also performed for 125I seeds of similar geometry and dimensions for the purpose of comparison. The new seed presents dosimetric characteristics that are very similar to that of the selectSeed. In comparison to the most extensively studied Amersham 6711 seed, the new one presents similar dosimetric characteristics with a slightly reduced dose rate constant (1.5%).

Polymer gel dosimetry close to an125I interstitial brachytherapy seed

Despite its advantages, the polymer gel-magnetic resonance imaging (MRI) method has not, as yet, been successfully employed in dosimetry of low energy/low dose rate photon-emitting brachytherapy sources such as 125I or 103Pd interstitial seeds. In the present work, two commercially available 125I seed sources, each of approximately 0.5 U, were positioned at two different locations of a polymer gel filled vial. The gel vial was MR scanned with the sources in place 19 and 36 days after seed implantation. Calibration curves were acquired from the coupling of MRI measurements with accurate Monte Carlo dose calculations obtained simulating the exact experimental setup geometry and materials. The obtained gel response data imply that while linearity of response is sustained, sensitivity (calibration curve slope) is significantly increased (approximately 60%) compared to its typical value for the 192Ir (or 60Co and 6 MV LINAC) photon energies. Water equivalence and relative energy response corrections of the gel cannot account for more than 3-4% of this increase, which, therefore, has to be mainly attributed to physicochemical processes related to the low dose rate of the sources and the associated prolonged irradiation time. The calibration data obtained from one 125I source were used to provide absolute dosimetry results for the other 125I source, which were found to agree with corresponding Monte Carlo calculations within experimental uncertainties. It is therefore suggested that, regardless of the underlying factors accounting for the gel dose response to 125I irradiations, polymer gel dosimetry of new 125I or 103Pd sources should be carried out as originally proposed by Heard and Ibbot (2004 J. Phys.: Conf. Ser. 3 221-3), i.e., by irradiating the same gel sample with the new low dose rate source, as well as with a well-characterized low dose rate source which will provide the dose calibration curve for the same irradiation conditions.

Experimental determination of the dosimetric characteristics for the I-Plant model 3600 125I brachytherapy source

The dosimetric characteristics for a new brachytherapy seed source (I-Plant model 3600) were measured using LiF thermoluminescent dosimeters and appropriate phantom materials in conformance with the methodology and guidance provided by the AAPM Task Group 43. The I-Plant model 3600 is the successor to the I-Plant model 3500. The major difference between these sources is that the model 3600 contains a leaded-glass core to provide radio-opacity (while the model 3500 contains a silver core), which does not produce spectral contamination upon neutron activation. The dose rate constant lambda for the model 3600 was determined to be 1.00 Gy h(-1) U(-1) (with a 6% overall relative standard deviation), compared to 1.01 cGy h(-1) U(-1) reported for the model 3500 in previous studies. The remaining dosimetric characteristics also are similar for both sources.

Dosimetry parameters of BARC OcuProsta I-125 seed source

A new model of 125I seed source, named OcuProsta seed, was designed and fabricated by Radiopharmaceuticals Division of Bhabha Atomic Research Centre for ophthalmic and interstitial applications. AAPM TG 43 recommended dosimetry parameters for this seed source were determined experimentally using TLD as well as by Monte Carlo (MC) simulation. Measured and MC calculated values of the dose rate constant (DRC) are 0.95 +/- 0.065 cGyh(-1)U(-1) and 0.972 +/- 0.005 cGyh(-1)U(-1), respectively. The mean of measured and calculated DRC (lambda = 0.96 cGyh(-1)U(-1)) was recommended for the clinical dosimetry of OcuProsta seed. Measured and MC calculated radial dose function, g(r), anisotropy function, F(r,theta), anisotropy factor and anisotropy constants are also found to be in good agreement to each other. Dosimetry parameters of OcuProsta seed were compared with the published values of similar in-design 125I seed sources. The DRC of BARC OcuProsta seed is very close to Amersham 6711 seed and is also comparable to the DRC of Best model 2301, Syncor PharmaSeed and Isotron selectSeed within the uncertainty of measurement/calculation. The g(r) of OcuProsta seed shows a difference of up to 10% in comparison to the g(r) values of the similar in-design seed sources. The values of anisotropy function of OcuProsta are 7-13% different from the anisotropy function of Amersham 6711 and Syncor PharmaSeed. The anisotropy constant of OcuProsta is close to Amersham 6711 seed while it is about 9% smaller than the anisotropy constant of Best model 2301 and Synchor PharmaSeed.

A technical evaluation of the Nucletron FIRST system: conformance of a remote afterloading brachytherapy seed implantation system to manufacturer specifications and AAPM Task Group report recommendations

The Fully Integrated Real‐time Seed Treatment (FIRST™) system by Nucletron has been available in Europe since November 2001 and is being used more and more in Canada and the United States. Like the conventional transrectal ultrasound implant procedure, the FIRST system utilizes an ultrasound probe, needles, and brachytherapy seeds. However, this system is unique in that it (1) utilizes a low‐dose‐rate brachytherapy seed remote afterloader (the seedSelectron), (2) utilizes 3D image reconstruction acquired from electromechanically controlled, nonstepping rotation of the ultrasound probe, (3) integrates the control of a remote afterloader with electromechanical control of the ultrasound probe for integrating the clinical procedure into a single system, and (4) automates the transfer of planning information and seed delivery to improve quality assurance and radiation safety. This automated delivery system is specifically intended to address reproducibility and accuracy of seed positioning during implantation. The FIRST computer system includes two software environments: SPOT PRO™ and seedSelectron™; both are used to facilitate treatment planning and brachytherapy seed implantation from beginning to completion of the entire procedure. In addition to these features, the system is reported to meet certain product specifications for seed delivery positioning accuracy and reproducibility, seed calibration accuracy and reliability, and brachytherapy dosimetry calculations. Consequently, a technical evaluation of the FIRST system was performed to determine adherence to manufacturer specifications and to the American Association of Physicists in Medicine (AAPM) Task Group Reports 43, 53, 56, 59, and 64 and recommendations of the American Brachytherapy Society (ABS). The United States Nuclear Regulatory Commission (NRC) has recently added Licensing Guidance for the seedSelectron system under 10 CFR 35.1000. Adherence to licensing guidance is made by referencing applicable AAPM Task Group recommendations. In general, results of this evaluation indicated that the system met its claimed specifications as well as the applicable recommendations outlined in the AAPM and ABS reports.

PACS number(s): 87.53.Xd, 87.53.Jw

Quality of permanent prostate implants using automated delivery with seedSelectron™ versus manual insertion of RAPID Strands™

BACKGROUND AND PURPOSE

To compare the quality of manually inserted RAPID Strand implants with automatically inserted selectSeed implants using volumetric and dosimetric parameters.

PATIENTS AND METHODS

Patients with T1 to T2 prostate carcinoma were treated with brachytherapy. The (125)I seeds were implanted in the prostate in three different ways: manual insertion of RAPID Strands (R); insertion of selectSeeds using the seedSelectron (S); a combination of both techniques: manual insertion of RAPID Strands in the left half of the prostate and insertion of selectSeeds with the seedSelectron in the right half of the prostate (RS). The comparison is based on implant and target specific parameters. The implant specific parameters, V(100), homogeneity index (HI), and natural dose ratio (NDR), were determined at the time of implantation and four weeks later. MR images taken four weeks after the implantation were used for the calculation of the target specific parameters: D(90), HI, external index (EI), and conformation number (CN).

RESULTS

We found no significant difference between the groups of implants (R, S, RS) for the implant specific parameters V(100), HI, and NDR at t(0) and neither at t(4w). For each group, the V(100) values decreased significantly with time between t(0) and t(4w). The target specific parameters D(90), HI, EI and CN were not significantly different between the groups. For the group of patients with both RAPID Strands and selectSeeds, we found a significant difference in D(90) between both halves of the prostate.

CONCLUSIONS

The dosimetry parameters of a newly introduced implant technique using an automatic seed afterloader were not significantly different from the parameters of a manual insertion technique using RAPID Strands. Since either technique has its advantages and disadvantages regarding seed migration, physics quality assurance, efficiency, logistics, and ease of use, it was decided to use both techniques and to continue evaluations.

Polymer gel water equivalence and relative energy response with emphasis on low photon energy dosimetry in brachytherapy

The water equivalence and stable relative energy response of polymer gel dosimeters are usually taken for granted in the relatively high x-ray energy range of external beam radiotherapy based on qualitative indices such as mass and electron density and effective atomic number. However, these favourable dosimetric characteristics are questionable in the energy range of interest to brachytherapy especially in the case of lower energy photon sources such as 103Pd and 125I that are currently utilized. In this work, six representative polymer gel formulations as well as the most commonly used experimental set-up of a LiF TLD detector-solid water phantom are discussed on the basis of mass attenuation and energy absorption coefficients calculated in the energy range of 10 keV-10 MeV with regard to their water equivalence as a phantom and detector material. The discussion is also supported by Monte Carlo simulation results. It is found that water equivalence of polymer gel dosimeters is sustained for photon energies down to about 60 keV and no corrections are needed for polymer gel dosimetry of 169Yb or 192Ir sources. For 125I and 103Pd sources, however, a correction that is source-distance dependent is required. Appropriate Monte Carlo results show that at the dosimetric reference distance of 1 cm from a source, these corrections are of the order of 3% for 125I and 2% for 103Pd. These have to be compared with corresponding corrections of up to 35% for 125I and 103Pd and up to 15% even for the 169Yb energies for the experimental set-up of the LiF TLD detector-solid water phantom.

MRI-guided prostate brachytherapy with single needle method—a planning study

BACKGROUND AND PURPOSE

Magnetic resonance image (MRI)-guided prostate brachytherapy with a conventional closed MR scanner is hampered by the limited access to the prostate. To handle this problem, we have designed a new implantation method, based on a patient lying in a closed MR scanner, a robotic device to be placed between patient's legs, and one needle with one insertion point.

MATERIALS AND METHODS

The MRI-guided robotic system inserts the needle into the prostate to deliver the seeds. Each time, the needle will be retracted to the rotation point (in the body), and the insertion angle can be changed. The possible angles of the needle are limited by the geometry of the closed MR scanner and the presence of the symphysis, rectum and urethra. We have done a planning study to investigate the feasibility of this single needle method.

RESULTS

The treatment plans made with the single needle method showed the possibility to cover the prostate with the prescribed dose without piercing the urethra or rectum and without pubic bone interference. The plans were comparable to the plans made for the multi parallel needle method, and the 144Gy isodose enclosed the prostate with a margin of about 2 mm. The planned angles of the needle were within the range of possible angles.

CONCLUSIONS

This planning study has shown the feasibility of adequate prostate coverage with the divergent single needle method within the limited space inside the closed MR scanner.

Results of permanent prostate brachytherapy, 13 years of experience at a single institution

BACKGROUND AND PURPOSE

To understand the influence of treatment techniques on the final outcome, as well as the relation of risk groups and of PSA nadir on the outcome, we reviewed our experience over more than 10 years.

PATIENTS AND METHODS

Patients were treated in the period 1989 through 2000. Available for this evaluation are 351 patients. The distribution of cases by T stage was T1a, b (9%), T1c (49%), T2 (42%), and by grading G1 (58%), G2 (38%), G3 (1%) and Gx (3%). The technique of plantation of seeds varied over the years, starting with single seeds using a Mick applicator (104 patients), followed by Rapid strands without (70) and with pre-planning (177). Risk groups are categorised as low (iPSA <10 ng/ml, T1-2, grade 1), 116 patients; intermediate (iPSA 10-20 ng/ml, or grade 2-3), 114 patients; and high risk (both factors, or iPSA >20 ng/ml), 121 patients. The mean follow-up time was 50 months, median 48 and range 24-123 months.

RESULTS

Overall actuarial survival at 5 and 7 years was 85 and 76%, respectively. Forty patients died, eight (2%) because of or with prostate cancer. Alive are 310 patients (88%), with 223 patients bNED (71%), 51 (16%) with PSA failure, 21 (7%) with local and 15 (5%) with distant recurrence. Total bNED was 72%. Although results are better since the introduction of Rapid strands, 79% bNED versus 54% bNED for single seeds (P = 0.14) also the increase in activity per cm(3) prostate volume accounts for this improvement. With pre-planning a significant better result (P < 0.03) is obtained as compared to single seeds or strands without planning. Categorisation into risk groups results in a significant difference (P < 0.007) of bNED with risk factors, respectively, 57% for the high, 75% for the intermediate and 89% for the low risk group. Also PSA nadir had a significant effect on outcome; patients who reach a nadir of < or =0.5 ng/ml have a 91% chance of cure.

CONCLUSIONS

Results of permanent seed implantation improved with the introduction of strands, however, better staging and the increase in activity per cm(3) prostate volume also contributed to this improvement. A significant better result was obtained with pre-planning. Categorisation in risk groups corresponds very well with treatment outcome. Finally, a strong relation is found with PSA nadir.

In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer

PURPOSE

To evaluate the potential of in vivo thermoluminescence dosimetry to estimate the accuracy of dose delivery in conformal high-dose-rate brachytherapy of prostate cancer.

METHODS AND MATERIALS

A total of 50 LiF, TLD-100 cylindrical rods were calibrated in the dose range of interest and used as a batch for all fractions. Fourteen dosimeters for every treatment fraction were loaded in a plastic 4F catheter that was fixed in either one of the 6F needles implanted for treatment purposes or in an extra needle implanted after consulting with the patient. The 6F needles were placed either close to the urethra or in the vicinity of the median posterior wall of the prostate. Initial results are presented for 18 treatment fractions in 5 patients and compared to corresponding data calculated using the commercial treatment planning system used for the planning of the treatments based on CT images acquired postimplantation.

RESULTS

The maximum observed mean difference between planned and delivered dose within a single treatment fraction was 8.57% +/- 2.61% (root mean square [RMS] errors from 4.03% to 9.73%). Corresponding values obtained after averaging results over all fractions of a patient were 6.88% +/- 4.93% (RMS errors from 4.82% to 7.32%). Experimental results of each fraction corresponding to the same patient point were found to agree within experimental uncertainties.

CONCLUSIONS

Experimental results indicate that the proposed method is feasible for dose verification purposes and suggest that dose delivery in transperineal high-dose-rate brachytherapy after CT-based planning can be of acceptable accuracy.

Monte Carlo dosimetry of a new 192Ir pulsed dose rate brachytherapy source

A new microSelectron pulsed dose rate source has been designed, containing two active pellets instead of one inactive and one active pellet contained in the old design, to facilitate the incorporation of higher activity up to 74 GBq (2 Ci). In this work, Monte Carlo simulation is used to derive full dosimetric data following the AAPM TG-43 formalism, as well as the dose rate per unit air kerma strength data in Cartesian, "away and along" coordinates for both source designs. The calculated dose rate constant of the new PDR source design was found equal to lambda=(1.121 +/- 0.006) cGy h(-1) U(-1) compared to lambda = (1.124 +/- 0.006) cGy h(-1) U(-1) for the old design. Radial dose functions of the two sources calculated using the point source approximated geometry factors were found in close agreement (within 1%) except for radial distances under 2 mm. At polar angles close to the longitudinal source axis at the sources' distal end, the new design presents increased anisotropy (up to 10%) compared to the old one due to its longer active core. At polar angles close to the longitudinal source axis at the sources' drive wire end however, the old design presents increased anisotropy (up to 18%) due to attenuation of emitted photons through the inactive Ir pellet. These differences, also present in "away and along" dose rate results, necessitate the replacement of treatment planning input data for the new microSelectron pulsed dose rate source.